Long-Term Outcomes in Patients with Acute Myelogenous Leukemia (AML) Following Allogeneic Stem Cell Transplantation (AlloSCT) for Relapse After Initial Autologous Bone Marrow Transplant (ASCT).
Mary-Elizabeth Percival(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Charalambos Andreadis(University of California, San Francisco), Weiyun Z. Ai(City College of San Francisco), Lawrence D. Kaplan(UCSF Helen Diller Family Comprehensive Cancer Center), Lloyd E. Damon(University of California, San Francisco), Thomas Martin(University of California, San Francisco), Charles Linker(University of California, San Francisco), Jeffrey L. Wolf(City College of San Francisco), Curt A. Ries(University of California, San Francisco), Sanghee Hong(Cleveland Clinic)
Cited by 0
Related Papers
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523